Phase I study of MLN8237—investigational Aurora A kinase inhibitor—in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia
Kevin R. Kelly(The University of Texas Health Science Center at San Antonio), Swaminathan P. Iyer(Houston Methodist)
Cited by 78
Related Papers
The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib
|Journal of Cellular and Molecular Medicine|2010|72
Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO‐dependent mechanism
|International Journal of Cancer|2012|53